The partnership will develop a Centre of Excellence on diabetes to advance treatment and care management in Southeast Asia.
SingHealth signed a Memorandum of Understanding (MoU) with Medtronic International Limited, a global medical device company, today. The partnership will develop a Centre of Excellence on diabetes to advance treatment and care management in Southeast Asia.
“There is an urgent need to tackle the diabetes challenge globally to reduce the burden of the disease. This will require active collaboration between different stakeholders to address the needs of our patients.
"We see this partnership with Medtronic as an exciting way forward in bringing better diabetes care to our patients, particularly through the adoption of innovative technology,” said Dr Bee Yong Mong, Head, SingHealth Duke-NUS Diabetes Centre and Senior Consultant, Department of Endocrinology, Singapore General Hospital.
The Centre of Excellence will work on various aspects diabetes care, from clinical service focusing on intensive insulin therapy, physician training for the latest diabetes management technologies, clinical research and adoption of new technologies, to patient awareness programmes.
The MoU was signed by Dr Bee Yong Mong and Mr Bob White, President, Medtronic (Asia-Pacific), at the opening of Medtronic’s Asia Pacific regional headquarters in Singapore.
Mr White said, “We are excited to work with SingHealth as our strategic partner to explore new approaches in solving challenges associated with diabetes care.”